scholarly journals Human umbilical cord blood cell therapy blocks the morphological change and recruitment of CD11b-expressing, isolectin-binding proinflammatory cells after middle cerebral artery occlusion

2009 ◽  
pp. n/a-n/a ◽  
Author(s):  
Christopher C. Leonardo ◽  
Aaron A. Hall ◽  
Lisa A. Collier ◽  
Craig T. Ajmo ◽  
Alison E. Willing ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Blood Cell ◽  
Cord Blood ◽  
Middle Cerebral Artery ◽  
Umbilical Cord Blood ◽  
Artery Occlusion ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Cord Blood Cell ◽  
Cerebral Artery Occlusion

scholarly journals MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice

Stem Cells ◽  
2016 ◽  
Vol 34 (1) ◽  
pp. 102-113 ◽  
Author(s):  
Jieli Chen ◽  
Ruizhuo Ning ◽  
Alex Zacharek ◽  
Chengcheng Cui ◽  
Xu Cui ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Diabetic Mice ◽  
Cord Blood Cell ◽  
Type 2 Diabetic

scholarly journals Human Umbilical Cord Blood Cell Grafts for Brain Ischemia

2009 ◽  
Vol 18 (9) ◽  
pp. 985-998 ◽  
Author(s):  
Dong-Hyuk Park ◽  
Cesar V. Borlongan ◽  
Alison E. Willing ◽  
David J. Eve ◽  
L. Eduardo Cruz ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Neural Lineage ◽  
Cord Blood Cell ◽  
Therapeutic Benefits ◽  
Umbilical Cord Blood Cell

Irreversible and permanent damage develop immediately adjacent to the region of reduced cerebral blood perfusion in stroke patients. Currently, the proven thrombolytic treatment for stroke, tissue plasminogen activator, is only effective when administered within 3 h after stroke. These disease characteristics should be taken under consideration in developing any therapeutic intervention designed to widen the narrow therapeutic range, especially cell-based therapy. Over the past several years, our group and others have characterized the therapeutic potential of human umbilical cord blood cells for stroke and other neurological disorders using in vitro and vivo models focusing on the cells' ability to differentiate into nonhematopoietic cells including neural lineage, as well as their ability to produce several neurotrophic factors and modulate immune and inflammatory reaction. Rather than the conventional cell replacement mechanism, we advance alternative pathways of graft-mediated brain repair involving neurotrophic effects resulting from release of various growth factors that afford cell survival, angiogenesis, and anti-inflammation. Eventually, these multiple protective and restorative effects from umbilical cord blood cell grafts may be interdependent and act in harmony in promoting therapeutic benefits for stroke.

Optimization of human umbilical cord blood cell dose for treatment of ALS

2006 ◽  
Vol 198 (2) ◽  
pp. 569-570
Author(s):  
S.N. Garbuzova-Davis ◽  
A.E. Willing ◽  
T Desjarlais ◽  
O. Kuzmenok ◽  
S. Seedial ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Cell Dose ◽  
Cord Blood Cell ◽  
Umbilical Cord Blood Cell
Sign in / Sign up

Export Citation Format

Share Document